Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection

O. Jurim, Paul Martin, D. J. Winston, C. Shackleton, C. Holt, J. Feller, M. Csete, A. Shaked, D. Imagawa, K. Olthoff, J. Y N Lau, R. W. Busuttil

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The effect of genciclovir prophylaxis on reinfection of hepatic allograffs by hepatitis B virus (HBV) was studied in 26 patients undergoing orthotopic liver transplantation (OLT) for decompensated cirrhosis due to HBV. Patients were randomized to receive either genciclovir (6 rag/kg/day intravenously for a total of 100 days) or acyclovir (10 mg/kg every 8 hours intravenously until discharged end then 800 mg orally every 6 hours) for a total of 100 days after OLT as part of a study of prophylaxis against cytomegalovirus infection. All patients received hepatitis B immunoglobulin (HBIG), 10,000 units intravenously, during the anhepatic phase, daily for the first 7 days after OLT, and then every 4 weeks for 6 months. Seven of 12 (58%) patients in the ganciclovir group developed recurrent HBV, compared with 6/14 (46%) of the acyclovir group (nonsignificant). No significant difference was observed in time to recurrent HBV in the ganciclovir group (mean 13.2 months) compared to the acyclovir group (mean 11 months). Our results suggest that ganciclovir administered prophylactically for 100 days after OLT does not prevent or delay graft reinfection by HBV.

Original languageEnglish
Pages (from-to)370-374
Number of pages5
JournalLiver Transplantation and Surgery
Volume2
Issue number5
StatePublished - Sep 25 1996
Externally publishedYes

Fingerprint

Ganciclovir
Chronic Hepatitis B
Hepatitis B virus
Liver Transplantation
Allografts
Acyclovir
Infection
Cytomegalovirus Infections
Hepatitis B
Immunoglobulins
Fibrosis
Transplants
Liver

ASJC Scopus subject areas

  • Hepatology
  • Surgery

Cite this

Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection. / Jurim, O.; Martin, Paul; Winston, D. J.; Shackleton, C.; Holt, C.; Feller, J.; Csete, M.; Shaked, A.; Imagawa, D.; Olthoff, K.; Lau, J. Y N; Busuttil, R. W.

In: Liver Transplantation and Surgery, Vol. 2, No. 5, 25.09.1996, p. 370-374.

Research output: Contribution to journalArticle

Jurim, O, Martin, P, Winston, DJ, Shackleton, C, Holt, C, Feller, J, Csete, M, Shaked, A, Imagawa, D, Olthoff, K, Lau, JYN & Busuttil, RW 1996, 'Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection', Liver Transplantation and Surgery, vol. 2, no. 5, pp. 370-374.
Jurim, O. ; Martin, Paul ; Winston, D. J. ; Shackleton, C. ; Holt, C. ; Feller, J. ; Csete, M. ; Shaked, A. ; Imagawa, D. ; Olthoff, K. ; Lau, J. Y N ; Busuttil, R. W. / Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection. In: Liver Transplantation and Surgery. 1996 ; Vol. 2, No. 5. pp. 370-374.
@article{42de954a3e914dad9d7ed5b828e3e099,
title = "Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection",
abstract = "The effect of genciclovir prophylaxis on reinfection of hepatic allograffs by hepatitis B virus (HBV) was studied in 26 patients undergoing orthotopic liver transplantation (OLT) for decompensated cirrhosis due to HBV. Patients were randomized to receive either genciclovir (6 rag/kg/day intravenously for a total of 100 days) or acyclovir (10 mg/kg every 8 hours intravenously until discharged end then 800 mg orally every 6 hours) for a total of 100 days after OLT as part of a study of prophylaxis against cytomegalovirus infection. All patients received hepatitis B immunoglobulin (HBIG), 10,000 units intravenously, during the anhepatic phase, daily for the first 7 days after OLT, and then every 4 weeks for 6 months. Seven of 12 (58{\%}) patients in the ganciclovir group developed recurrent HBV, compared with 6/14 (46{\%}) of the acyclovir group (nonsignificant). No significant difference was observed in time to recurrent HBV in the ganciclovir group (mean 13.2 months) compared to the acyclovir group (mean 11 months). Our results suggest that ganciclovir administered prophylactically for 100 days after OLT does not prevent or delay graft reinfection by HBV.",
author = "O. Jurim and Paul Martin and Winston, {D. J.} and C. Shackleton and C. Holt and J. Feller and M. Csete and A. Shaked and D. Imagawa and K. Olthoff and Lau, {J. Y N} and Busuttil, {R. W.}",
year = "1996",
month = "9",
day = "25",
language = "English",
volume = "2",
pages = "370--374",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection

AU - Jurim, O.

AU - Martin, Paul

AU - Winston, D. J.

AU - Shackleton, C.

AU - Holt, C.

AU - Feller, J.

AU - Csete, M.

AU - Shaked, A.

AU - Imagawa, D.

AU - Olthoff, K.

AU - Lau, J. Y N

AU - Busuttil, R. W.

PY - 1996/9/25

Y1 - 1996/9/25

N2 - The effect of genciclovir prophylaxis on reinfection of hepatic allograffs by hepatitis B virus (HBV) was studied in 26 patients undergoing orthotopic liver transplantation (OLT) for decompensated cirrhosis due to HBV. Patients were randomized to receive either genciclovir (6 rag/kg/day intravenously for a total of 100 days) or acyclovir (10 mg/kg every 8 hours intravenously until discharged end then 800 mg orally every 6 hours) for a total of 100 days after OLT as part of a study of prophylaxis against cytomegalovirus infection. All patients received hepatitis B immunoglobulin (HBIG), 10,000 units intravenously, during the anhepatic phase, daily for the first 7 days after OLT, and then every 4 weeks for 6 months. Seven of 12 (58%) patients in the ganciclovir group developed recurrent HBV, compared with 6/14 (46%) of the acyclovir group (nonsignificant). No significant difference was observed in time to recurrent HBV in the ganciclovir group (mean 13.2 months) compared to the acyclovir group (mean 11 months). Our results suggest that ganciclovir administered prophylactically for 100 days after OLT does not prevent or delay graft reinfection by HBV.

AB - The effect of genciclovir prophylaxis on reinfection of hepatic allograffs by hepatitis B virus (HBV) was studied in 26 patients undergoing orthotopic liver transplantation (OLT) for decompensated cirrhosis due to HBV. Patients were randomized to receive either genciclovir (6 rag/kg/day intravenously for a total of 100 days) or acyclovir (10 mg/kg every 8 hours intravenously until discharged end then 800 mg orally every 6 hours) for a total of 100 days after OLT as part of a study of prophylaxis against cytomegalovirus infection. All patients received hepatitis B immunoglobulin (HBIG), 10,000 units intravenously, during the anhepatic phase, daily for the first 7 days after OLT, and then every 4 weeks for 6 months. Seven of 12 (58%) patients in the ganciclovir group developed recurrent HBV, compared with 6/14 (46%) of the acyclovir group (nonsignificant). No significant difference was observed in time to recurrent HBV in the ganciclovir group (mean 13.2 months) compared to the acyclovir group (mean 11 months). Our results suggest that ganciclovir administered prophylactically for 100 days after OLT does not prevent or delay graft reinfection by HBV.

UR - http://www.scopus.com/inward/record.url?scp=9544235159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9544235159&partnerID=8YFLogxK

M3 - Article

C2 - 9346678

AN - SCOPUS:9544235159

VL - 2

SP - 370

EP - 374

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 5

ER -